Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.

TitleBrief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
Publication TypePublication
Year of Publication2017
AuthorsKahn JA, Xu J, Kapogiannis BG, Sleasman JW
JournalJ Acquir Immune Defic Syndr
Volume75
Issue2
Pagination241-245
Date Published2017 06 01
ISSN1944-7884
KeywordsAntibodies, Neutralizing, Antibodies, Viral, Antibody Formation, Female, HIV Infections, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Humans, Immunoassay, Immunoglobulin G, Papillomavirus Infections, Vaccination, Young Adult
Abstract

<p>We compared antibody responses of HIV-infected young women to the human papillomavirus (HPV) 6, 11, 16, and 18 vaccine using total immunoglobulin (Ig) G Luminex immunoassay (LIA) and competitive Luminex immunoassay (cLIA) assays. HPV18 seropositivity after HPV vaccination as measured with IgG LIA remained high (98%) 48 weeks after vaccination, in contrast with seropositivity as measured with cLIA (73%). Seropositivity rates at week 48 as measured by both IgG LIA and cLIA remained high for HPV6, 11, and 16 (93.5%-100%). These results suggest that the lower rate of seropositivity to HPV18 when cLIA vs. IgG LIA is used is a function of the assay and does not imply lower vaccine immunogenicity.</p>

DOI10.1097/QAI.0000000000001355
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID28291048
PubMed Central IDPMC5429191
Grant ListM01 RR020359 / RR / NCRR NIH HHS / United States
U01 HD040474 / HD / NICHD NIH HHS / United States
U01 HD040533 / HD / NICHD NIH HHS / United States
UL1 RR024134 / RR / NCRR NIH HHS / United States